Clinical Trial Detail

NCT ID NCT03113643
Title SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

acute myeloid leukemia

myelodysplastic syndrome

Therapies

Azacitidine + tagraxofusp-erzs + Venetoclax

Azacitidine + tagraxofusp-erzs

Age Groups: adult senior

No variant requirements are available.